Navigation Links
Vion Pharmaceuticals to Appeal Nasdaq Delisting
Date:5/8/2008

Company to Request Hearing with Listing Qualifications Panel

NEW HAVEN, Conn., May 8 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that it had received a letter, dated May 7, 2008, from The Nasdaq Stock Market Inc. (Nasdaq) stating that the Company's common stock will be delisted from the Nasdaq Capital Market as of the opening of business on May 16, 2008 because the Company does not comply with Marketplace Rule 4310(c)(3) which requires the Company to have a minimum of $2,500,000 in stockholders' equity, or $35,000,000 market value of listed securities, or $500,000 of net income from continuing operations for the most recently completed fiscal year or two of the three most recently completed fiscal years. The Company has the right to appeal the Nasdaq Staff determination to a Nasdaq Listings Qualifications Panel. If the Company requests a hearing no later than May 14, 2008, the request for a hearing will automatically stay the delisting of the Company's common stock until the Panel reaches a decision.

The Company intends to request a hearing before May 14, 2008. There can be no assurance that the Panel will grant the Company's request for continued listing.

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with temozolomide in brain tumors, and
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Marriagelifeinsurance.com has released a new blog ... couples. , Senior citizens can purchase a joint ... loved ones. A joint policy is cheaper, but will ... , Life insurance can be used to cover ... be purchased online, as the application process is simple ...
(Date:10/1/2014)... 2014 Lifeinsurance-policy.com has released a ... life insurance prices for smokers. , Smoking will always ... Comparing quotes is the best method to find affordable ... customers who need coverage. , Whole life insurance ... the policy. Since the coverage is permanent, the initial ...
(Date:10/1/2014)... WASHINGTON, D.C. and ATLANTA (PRWEB) October 01, ... and information security executive networking and relationship-marketing ... the 2014 Information Security Executive® and Project ... Executives include top-ranking decision makers representing organizations ... and academics. Projects include large-scale technology endeavors ...
(Date:10/1/2014)... N.C. A new genetic finding from Duke Medicine ... anxiety and depression might also be hard-wired to gain ... and heart disease. , An estimated 13 percent of ... genetic susceptibility, and knowing this could help them reduce ... diet, exercise and stress management. , "Genetic susceptibility, psychosocial ...
(Date:10/1/2014)... 2014 Innovations announces the upcoming airing ... on Monday, October 20, 2014 at 7:30 a.m. EST/PT ... go behind the scenes to learn about Break the ... explore the practical help and information Break the Cycle ... warning signs of abuse, how to navigate the legal ...
Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Affordable Whole Life Insurance Premiums for Smokers! 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Gene interacts with stress and leads to heart disease in some people 2Health News:Innovations to Explore Breakthroughs in Health and Wellness in Upcoming Episode Airing Monday, October 20, 2014 via Discovery Channel 2
... studies examine the use of the nucleoside polymerase inhibitor, ... reports appear in the August issue of Hepatology ... on behalf of the American Association for the Study ... at Wiley Interscience ( www.interscience.wiley.com ). , The ...
... scientists are attempting to recognize and treat schizophrenic disorders ... will improve the prognosis, which has often been unfavorable. ... ( Dtsch Arztebl Int 2008; 105[30]: 532-9), ... at Cologne University describes the current state of research ...
... Offer Groundbreaking The Prevention Plan to Employers, ... Medicine,( http://www.USPreventiveMedicine.com ), the leader in disease ... they have formed a,strategic alliance that will ... offer U.S. Preventive Medicine,s groundbreaking prevention program ...
... best-of-breed security deployment helps protect Verispan,s HIPAA-compliant, de-identified, patient-centric market ... ... Reston, VA and Ottawa, ON (PRWEB) ... security software company specializing in host intrusion defense, today announced ...
... Attila Molnar ... 31 The Management Board of Bayer AG,announced today that ... the Senior Bayer Representative in North America,succeeding Dr. Attila Molnar, ... effective October 1, 2008. Bayer Corporation is the U.S.,subsidiary of ...
... In Recognition of World,Breastfeeding Week, Mary Ann ... online access to Breastfeeding Medicine, (http://www.liebertpub.com/bfm ) ... a MEDLINE journal, the official publication of ... peer-reviewed medical journal,providing physicians with the evidence-based ...
Cached Medicine News:Health News:New treatment therapy helps inhibit hepatitis C 2Health News:U.S. Preventive Medicine(R) Forms Strategic Alliance with Physicians Planning Group 2Health News:U.S. Preventive Medicine(R) Forms Strategic Alliance with Physicians Planning Group 3Health News:Verispan Calls on Third Brigade for Added Data Protection 2Health News:Verispan Calls on Third Brigade for Added Data Protection 3Health News:Photos: Bayer Names New U.S. CEO 2Health News:Photos: Bayer Names New U.S. CEO 3Health News:Photos: Bayer Names New U.S. CEO 4Health News:Mary Ann Liebert, Inc. Provides Complimentary Online Access to Breastfeeding Medicine for the Month of August 2
(Date:9/30/2014)... -- Decision Resources Group finds that the Asia Pacific ... China , India , Japan ... 2023. Dental implant procedure volumes will grow as physicians are increasingly ... Other key findings from Decision Resources Group,s coverage of the ... , Dental implant penetration: Penetration of dental implants among the ...
(Date:9/30/2014)... 2014 According to ... by Product [Enzymes (Glycosyltransferase, Neuraminidase, Glycosidase), Instruments ... Application (Immunology, Oncology) & by End User ... MarketsandMarkets, provides a detailed overview of the ... trends, and strategies impacting the global glycomics ...
(Date:9/30/2014)...   Easy Breathe , the fastest growing online ... it now offers the revolutionary AirSense CPAPs ... sleep apnea therapy devices with internal cellular modems.  This ... and share real-time data on each user,s quality of ... In addition, the internal modem allows the CPAP to ...
Breaking Medicine Technology:Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 2Asia Pacific Dental Implant Market Will Grow at a Strong Rate Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 2Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 3Easy Breathe Now Offers World's First "Smart" CPAP Device to Treat Sleep Apnea 4
... be treated with nephron-sparing approaches when possibleLINTHICUM, Md., ... the affected kidney) is not the best treatment ... patients at risk for chronic kidney disease and ... nephrectomy, thermal ablation and active surveillance, minimize these ...
... Pomegranate juice may slow the progression ... long-term research results being presented at the 104th ... (AUA). Researchers found that men who have undergone ... drinking pomegranate juice. The two-stage clinical trial ...
Cached Medicine Technology:AUA Guideline: Full Kidney Removal Not Necessary for All Kidney Tumors 2AUA Guideline: Full Kidney Removal Not Necessary for All Kidney Tumors 3Men Treated for Localized Prostate Cancer Could Benefit From Pomegranate Juice Consumption 2
... Renu Multiplus no rub formula is ... available today. All steps in one bottle ... disinfects, stores your soft contact lenses and ... the only multi-purpose solution that contains Hydranate, ...
Children's Half Trial Frames...
... comes at a very attractive price. ,The following adjustments can ... 4 1/8" to 5 1/2" (98 to 135mm), Nose ... PD adjustable 24 to 40mm on each side (48mm to ... left - 120 to 0 to 135 , right - ...
... Sterile Bad-Parker blades offer the superior ... steel technology, plus the exclusive Rib-Back ... strength. Brad-Parker brand producer offer the ... and disposable scalpels. Every blade is ...
Medicine Products: